Zambia ZAMRA Medical Device Registry Teardown: Manufacturers & LTRs
A data-driven teardown of Zambia's ZAMRA medical device and IVD registry. Explore risk-class splits, country of origin trends, and LRP channel concentration.
Executive Summary
We are entering Zambia and need to understand the active medical device and in vitro diagnostic (IVD) market and the licensed channel: how many medical devices are registered with the Zambia Medicines Regulatory Authority (ZAMRA), what is the risk-class split, which manufacturer countries dominate, and which local technical representatives (LTRs) hold the registrations? How does this impact our regulatory representation and distribution strategy?
According to our database analysis of the official ZAMRA registered products register (Allied Substances section, snapshot dated June 22, 2026), the register lists 230 active medical device and IVD registrations within the broader allied products database (which contains 1,113 total registered records). Within this dataset:
- Balanced Risk Profile: The 230 active registrations split by risk class into Class A (23, 10.0%), Class B (80, 34.8%), Class C (52, 22.6%), and Class D (53, 23.0%), representing a mature risk-based classification footprint.
- Heavy Import Reliance: Over 90% of the registered medical devices are manufactured outside Zambia. The leading manufacturer country of origin is India with 52 registrations (22.6%), followed by China (25, 10.9%), Thailand (23, 10.0%), and the United States (25, 10.9% combined USA and United States of America), showing a strong presence of both Asian diagnostic providers and Western hardware multinationals.
- Top Manufacturers: Leading manufacturer entities on the register are dominated by IVD and medical consumable providers. The top manufacturers include CTK Biotech (12 registrations), Raymond Lifestyle Limited (12), SSL Manufacturing (Thailand) Ltd (8), Suretex Limited (7), Thai Nippon Rubber (6), Cepheid (6), Meril Diagnostics Pvt. Ltd. (6), and Medsource Ozone Biomedicals Pvt. Ltd. (6).
In contrast to the fragmented manufacturing base, the local distribution channel is highly concentrated. Out of dozens of registered local entities, a small group of local distributors holds a dominant share of registrations. The top local technical representatives (LTRs)—International Drug Company (32 registrations combined), Sterelin Medical & Diagnostics LTD (23), and Phillips Pharmaceuticals (Zambia) Limited (12)—control a massive share of all device registrations. For foreign manufacturers, this concentration indicates that partnering with an established LTR is critical for rapid market access, but requires careful negotiation to manage registration ownership and prevent channel lock-in.
Introduction to Zambia's MedTech Market and ZAMRA
Zambia, located in Southern Africa, is a landlocked country experiencing steady healthcare infrastructure development. The country’s medical device and diagnostics market relies heavily on imports, which account for approximately 95% of healthcare technology by value. The primary driver of demand is the public health sector, managed by the Ministry of Health (MoH) and supported by international donor organizations (such as USAID, the Global Fund, and WHO), alongside a growing private healthcare network in urban centers like Lusaka, Ndola, and Kitwe.
The commercialization, importation, and distribution of medical devices and IVDs in Zambia are regulated by the Zambia Medicines Regulatory Authority (ZAMRA). Formerly known as the Pharmaceutical Regulatory Authority, ZAMRA was established under the Medicines and Allied Substances Act (No. 3) of 2013. The authority is tasked with ensuring that all medicines, allied substances, and medical devices used in Zambia are safe, efficacious, and of high quality.
While historically focused on pharmaceuticals and herbal medicines, ZAMRA has aggressively structured its medical device regulatory oversight since the enactment of the 2013 Act. The authority has transitioned from simple import permits to a formal product registration and marketing authorization system. All imported medical devices must be registered with ZAMRA before they can be legally placed on the Zambian market. Below, we perform a deep database teardown of the 230 active entries on the ZAMRA register to map the competitive dynamics.
The Legal Framework: Medicines and Allied Substances Act No. 3 of 2013
The regulation of medical devices in Zambia operates under a specific legal and administrative stack:
- Medicines and Allied Substances Act No. 3 of 2013: The foundational statute that grants ZAMRA its authority to regulate all medical products, including medical devices, in vitro diagnostics (IVDs), and health technologies.
- Risk-Based Classification: Zambia aligns its classification with the International Medical Device Regulators Forum (IMDRF) standards:
- Class A (Low Risk): Non-sterile bandages, basic surgical drapes, simple medical instruments.
- Class B (Low-to-Moderate Risk): Syringes, clinical thermometers, basic diagnostic reagents, condoms.
- Class C (Moderate-to-High Risk): Infusion pumps, anesthesia systems, complex IVD kits, blood glucose monitors.
- Class D (High Risk): Pacemakers, cardiovascular stents, orthopedic joint replacements, HIV rapid diagnostic tests.
- The LTR Mandate: Any foreign manufacturer wishing to register a device in Zambia must appoint a local company to act as their Local Technical Representative (LTR). The LTR is legally responsible for submitting the technical dossier, managing the registration, executing recalls, and reporting adverse events. Under ZAMRA rules, the registration certificate is issued in the name of the LTR, granting that representative substantial control over the product's market access.
- 5-Year Validity: Once registered, a ZAMRA marketing authorization is valid for 5 years. The LTR must ensure the device remains compliant with all post-market surveillance and quality control regulations during this period.
Dataset Walkthrough: Data Volume and Completeness
The data analyzed in this teardown is extracted from ZAMRA's public registered products register (specifically the Allied Substances section, snapshot dated June 22, 2026). It represents the most complete picture of ZAMRA's device clearances.
While the raw ZAMRA Allied Substances database contains 1,113 unique rows, this database includes a large number of non-device products, such as disinfectants, nutritional supplements, and alternative medicines. To isolate the medical device and IVD market, we applied a strict filter using:
- Risk classifications (
Class A,Class B,Class C,Class D). - Certificate prefixes (
ZAMRA-MDRorZAMRA-CDequivalents). - Targeted device-specific keywords (e.g.,
analyser,condom,diagnostic,reagent,catheter).
This rigorous process isolated 230 active medical device and IVD registrations. Within this filtered dataset:
- High Completeness: Key fields such as
brand_name,classification_name,registrant,localtechnical_representative, andvalidity_statuscarry a 95%+ fill rate. - Manufacturer Location Nulls: Approximately 66 rows (28.7%) lack specific manufacturer location details in the database or list them as
None. We report these as "Unspecified" rather than omitting them, ensuring full transparency in our data. - Temporal Context: The dates parsed from
certificate_issue_dateandapp_expiry_Dateshow that all active registrations fall within the current validity window, with the latest expiring in 2031.
Quantitative Teardown: Risk-Class Splits
Analyzing the distribution of the 230 active registrations across ZAMRA's risk classes provides a clear view of the types of medical technologies currently cleared for the Zambian market:
| ZAMRA Risk Class | Active Registrations | Percentage | Description / Example Devices |
|---|---|---|---|
| Class A | 23 | 10.0% | Low-risk consumables, basic surgical drapes, specimen containers |
| Class B | 80 | 34.8% | Low-to-moderate risk devices, condoms, basic clinical reagents |
| Class C | 52 | 22.6% | Moderate-to-high risk devices, glucose meters, diagnostic analyzers |
| Class D | 53 | 23.0% | High-risk devices, HIV rapid tests, complex implantables |
| Other / Unclassified | 22 | 9.6% | Antiseptic/disinfectants, nutritional supplements, and missing labels |
| Total | 230 | 100.0% | Complete Filtered Medical Device Registry |
Analysis of Risk Class Splits
The classification data reveals that Class B is the largest single class, accounting for 34.8% of the register. This is heavily driven by registrations for latex condoms and basic diagnostic test kits. Class C and Class D combined account for 45.6% of all registrations. This high proportion of moderate-to-high and high-risk registrations reflects the clinical priority given by ZAMRA to regulating critical diagnostic tools (such as HIV, malaria, and tuberculosis rapid test kits) and complex medical equipment imported for tertiary hospitals.
ZAMRA Active Registrations by Risk Class:
Class A: [==========] 23 (10.0%)
Class B: [==================================] 80 (34.8%)
Class C: [======================] 52 (22.6%)
Class D: [=======================] 53 (23.0%)
Other: [==========] 22 (9.6%)
Manufacturer Country of Origin: India and China Lead the Footprint
Analyzing the manufacturing origin of the registered devices highlights Zambia's near-total reliance on foreign imports and the geographic composition of its medical supply chain:
| Rank | Country of Origin | Registered Devices | Percentage of Registry | Key Product Segments |
|---|---|---|---|---|
| 1 | India | 52 | 22.6% | Diagnostics, rapid test kits, consumables, hospital hardware |
| 2 | China | 25 | 10.9% | Rapid diagnostic reagents, surgical consumables, syringes |
| 3 | United States (USA & US) | 25 | 10.9% | Complex diagnostics, molecular test kits, analyzers |
| 4 | Thailand | 23 | 10.0% | Latex condoms, diagnostic reagents |
| 5 | France | 6 | 2.6% | In vitro diagnostics, culture media |
| 6 | South Korea | 6 | 2.6% | Rapid tests, immunoassay systems |
| 7 | Malaysia | 4 | 1.7% | Latex gloves, catheters |
| 8 | Germany | 4 | 1.7% | Clinical analyzers, premium instruments |
| — | Unspecified / Null | 66 | 28.7% | Unlabeled data entries |
| Total | Zambia Device Imports | 230 | 100.0% | Allied Substances Registry |
The India-China Manufacturing Core
Indian and Chinese manufacturers represent the foundational core of the Zambian registry. Combined, India (22.6%) and China (10.9%) account for more than a third of all active registrations. Indian firms like Meril Diagnostics and Chinese players like CTK Biotech supply high-volume diagnostic reagents, rapid tests, and basic consumables that fit the budget constraints of the Zambian public health system.
Thailand's Condom Footprint
Thailand's high position on the list (10.0% of the registry) is a result of a highly concentrated category: latex condoms. Global manufacturers like SSL Manufacturing (Thailand) (Durex brand) and Suretex Limited manufacture their products in Thailand and hold extensive registrations in Zambia. These products are imported in large volumes to support public health campaigns and national family planning programs.
The United States and Premium Molecular Testing
The United States (10.9%) remains a major supplier of premium diagnostics and molecular testing platforms. This footprint is led by companies like Cepheid, which registers its molecular diagnostic systems and GeneXpert cartridges in Zambia. These systems are widely used in country-wide tuberculosis and HIV molecular monitoring programs funded by USAID and the Global Fund.
Local Technical Representative (LTR) Channel Concentration
To commercialize a medical device or IVD in Zambia, foreign manufacturers must partner with a registered local firm that acts as their LTR. Under ZAMRA rules, the LRP/LTR holds the product registration certificate. Our analysis of the local technical representatives on the register reveals a high degree of channel concentration:
| Rank | LTR / Distributor Name | Active Registrations | Share of Registry | Key Partnerships & Focus Areas |
|---|---|---|---|---|
| 1 | International Drug Company (inc. variants) | 32 | 13.9% | Abbott Diagnostics, various Indian consumable manufacturers |
| 2 | Sterelin Medical & Diagnostics LTD | 23 | 10.0% | Reckitt Benckiser (Durex), molecular diagnostics, IVDs |
| 3 | Phillips Pharmaceuticals (Zambia) Ltd | 12 | 5.2% | Multinationals, premium consumables, cardiovascular tools |
| 4 | Venus Leo Investments | 12 | 5.2% | Asian diagnostics, point-of-care test kits |
| 5 | Prime Pharmaceuticals Limited (inc. variants) | 15 | 6.5% | Consumables, syringes, basic hospital hardware |
| 6 | Melcome Pharmaceuticals Limited | 10 | 4.3% | Rapid diagnostics, generic clinical supplies |
| 7 | Premier Medical | 7 | 3.0% | Laboratory reagents, rapid test kits |
| — | Unspecified / Null | 20 | 8.7% | Missing LTR associations |
| Total | Top LTR Channel Share | 111 | 48.3% | Top 7 LTRs control nearly half of the register |
Strategic Implications of LTR Concentration
The top 7 LTRs control 48.3% of all medical device registrations on the active ZAMRA list. The two largest players—International Drug Company (32 registrations) and Sterelin Medical & Diagnostics LTD (23 registrations)—alone hold nearly 24% of the entire register.
This concentration of registrations in a few hands presents several strategic challenges and opportunities for foreign medtech manufacturers entering Zambia:
- Immediate Regulatory Infrastructure: Partnering with a top-tier LTR like International Drug Company or Sterelin provides access to an established regulatory department, a pre-existing e-services account with ZAMRA, and good working relationships with the authority.
- Channel Lock-In Risk: Under Zambia's Medicines and Allied Substances Act of 2013, the marketing authorization is tied directly to the LTR. If a manufacturer decides to change distributors due to poor sales performance or compliance issues, transferring the registration certificate to a new LTR requires the voluntary cooperation of the incumbent LTR. If the relationship has deteriorated, the incumbent can block the transfer by refusing to surrender the certificate, forcing the manufacturer to start the 9-to-12 month registration process from scratch.
- Cross-Portfolio Conflict: Because the top LTRs hold extensive portfolios, they often represent competing product lines. Foreign manufacturers must perform rigorous competitive checks before appointing an LTR to ensure their products will receive active sales support rather than being buried in a large distributor catalog.
Temporal Trends: Accelerating ZAMRA Activity
Analyzing the years in which the active ZAMRA certificates were issued reveals a clear trend of increasing regulatory enforcement:
| Certificate Issue Year | Active Registrations | Percentage | Key Regulatory Milestone |
|---|---|---|---|
| 2021 | 9 | 3.9% | Baseline registrations |
| 2022 | 27 | 11.7% | Post-pandemic recovery |
| 2023 | 23 | 10.0% | Introduction of updated guidelines |
| 2024 | 39 | 17.0% | Mandatory enforcement push |
| 2025 | 78 | 33.9% | Peak registration activity |
| 2026 (partial) | 54 | 23.5% | Mid-year run-rate |
| Total | 230 | 100.0% | Active Register |
The data shows a massive spike in registrations starting in 2024 and peaking in 2025, with 33.9% of all active registrations issued in 2025. This acceleration is a direct result of ZAMRA's enforcement push. Following the pandemic, ZAMRA transitioned its registration database to the online e-Services portal and began strictly audits of import permits at borders. Importers who previously relied on ad-hoc import permits were forced to transition to formal 5-year marketing authorizations, creating a backlog of submissions that cleared throughout 2025.
Because ZAMRA certificates are valid for exactly 5 years, the expiry dates show a corresponding ramp, with 70 registrations expiring in 2030 and 54 expiring in 2031. Manufacturers must plan their renewal submissions at least 6 months before these dates to prevent importation blocks.
Step-by-Step ZAMRA Registration Process
For foreign manufacturers planning to enter the Zambian market, navigating the ZAMRA registration process requires a structured approach. Below is the step-by-step workflow:
graph TD
A[Appoint Local Technical Representative] --> B[Prepare STED Product Dossier]
B --> C[Format English Labeling & IFU]
C --> D[Submit via ZAMRA e-Services Portal]
D --> E{ZAMRA Evaluation}
E -->|Class A: 3-9 Months| F[Marketing Authorization Issued]
E -->|Class B-D: 9-12 Months| F
F --> G[5-Year Maintenance & Vigilance]
Step 1: Appoint a Local Technical Representative (LTR)
Foreign manufacturers must execute a power of attorney appointing a legally registered Zambian wholesale dealer or regulatory agency to act as their LTR. The LTR must hold a valid ZAMRA pharmaceutical/allied substances wholesale license.
Step 2: Prepare the Product Dossier (STED Format)
Applicants must compile a technical dossier following the GHTF Summary Technical Documentation (STED) format. Key elements include:
- Device description and specifications.
- Design verification and validation data (clinical evidence, biocompatibility, sterilization validation).
- Essential Principles Checklist demonstrating safety and performance compliance.
- Risk management file (compliant with ISO 14971).
- Manufacturing process description and proof of Quality Management System (QMS) compliance (ISO 13485:2016 certificate).
Step 3: Format Labeling and Instructions for Use (IFU)
All labeling, packaging, and IFUs must be in English. The mock-ups must clearly display:
- The name and address of the manufacturer.
- The name and address of the Zambian LTR.
- Batch/lot numbers and expiry dates.
- Clear storage instructions.
Step 4: Submission and Screening
The LTR submits the dossier electronically via the ZAMRA e-Services / IRIMS portal. Upon submission, the portal generates a screening invoice. The LTR must pay the screening fee to initiate the technical review.
Step 5: Technical Evaluation
ZAMRA performs a technical evaluation of the dossier. During this phase, the authority may issue queries/deficiencies. The applicant typically has 30 to 60 days to respond. Timelines vary by risk class:
- Class A: 3 to 9 months.
- Class B, C, and D: 9 to 12 months.
Step 6: Approval and Certificate Issuance
Upon successful review, ZAMRA issues a Marketing Authorization certificate. The certificate lists the manufacturer, the device details, and the local LTR. The registration is valid for 5 years.
Strategic Partner Selection and Quality Agreement Guidelines
Given the high degree of LTR concentration and the regulatory lock-in created by ZAMRA rules, foreign manufacturers must utilize a robust negotiation playbook when appointing local representatives.
The LTR Selection Decision Tree
Before signing a distribution agreement, manufacturers should use the following decision matrix:
Does the distributor have a ZAMRA Wholesale License?
|
+-----------------+-----------------+
| Yes | No
Does LTR portfolio contain DO NOT APPOINT
competing lines?
|
+----------+----------+
| Yes | No
Negotiate category exclusivity Can LTR manage ZAMRA e-Services?
and dedicated sales support |
+-------------+-------------+
| Yes | No
APPOINT LTR DO NOT APPOINT
Essential Quality Agreement Clauses
To mitigate the risk of channel lock-in, the formal agreement between the manufacturer and the local LTR must include the following clauses:
- Voluntary Registration Transfer: "The Local Responsible Person/LTR agrees to transfer the product registration certificate and all associated marketing authorizations to another registered LTR within 30 days of receiving a written termination notice from the manufacturer, without requiring further compensation."
- Regulatory Power of Attorney: "The LTR shall maintain the registration on behalf of the manufacturer, and all regulatory data, dossiers, and e-Services credentials associated with the manufacturer's products remain the sole property of the manufacturer."
- Separation of Roles: "The distributor is authorized as the commercial importer only. The manufacturer reserves the right to appoint a third-party regulatory consulting firm to act as the primary LRP/LTR of record, allowing commercial distribution to be split among multiple wholesale partners."
Comparison of Southern and Eastern African Registries
Understanding how Zambia's registry compares structurally to its regional neighbors helps regional managers allocate regulatory budgets effectively:
| Metric | Zambia (ZAMRA) | South Africa (SAHPRA) | Kenya (PPB) | Tanzania (TMDA) |
|---|---|---|---|---|
| Registry Scope | Products (230 devices) | Establishment Licences (3,000) | Products (831 retained) | Products (4,671 registered) |
| Local Rep Rule | Local Responsible Person | Authorized Representative | Local Technical Rep | Local Representative |
| Validity Period | 5 Years | Annual Renewal | 5 Years (Annual retention) | 5 Years (Annual retention) |
| Fee Structure | Class-based (USD/ZMW) | Licence type (R15k–R26k) | Class-based (USD) | Class-based (USD) |
| Evaluation Route | Dossier review / Reliance | Operational audit | Dossier review / Reliance | Dossier review / Reliance |
| Primary Law | Medicines & Allied Act 2013 | Medicines Act 101 of 1965 | Pharmacy Act Cap 244 | Food, Drugs & Cos. Act 2003 |
Key Takeaway for Regional Managers
While South Africa (SAHPRA) focuses heavily on establishment licensing (controlling the entities allowed to handle devices), Zambia (ZAMRA), Kenya (PPB), and Tanzania (TMDA) focus on product-level registration. In Zambia and Kenya, this product registration is tightly bound to a single local representative, creating a commercial gate. Conversely, South Africa's establishment license allows foreign manufacturers to sell to any licensed distributor, offering greater distribution flexibility but requiring higher initial compliance setup costs for local partners.
Conclusion and Key Takeaways
Entering the Zambian MedTech market offers solid growth opportunities, particularly in diagnostics and clinical consumables. However, commercial success is gated by ZAMRA's regulatory requirements:
- Audit Your Partners: With nearly 50% of registrations held by just 7 LTRs, ensure your chosen partner has active regulatory capacity and does not represent direct competitors.
- Draft Defensive Agreements: Never allow a distributor to register your devices without a signed Quality Agreement that mandates voluntary registration transfer and defines transfer costs.
- Track Expiries: ZAMRA's 5-year validity window requires proactive tracking. With a massive cohort of registrations set to expire in 2030 and 2031, plan renewals early to avoid customs blockages at the border.
Frequently Asked Questions (FAQs)
How many medical devices are registered with ZAMRA in Zambia?
As of June 2026, there are 230 active medical device and IVD registrations listed within the Allied Substances register. The broader allied database contains 1,113 unique rows, but the majority represent nutritional supplements, disinfectants, and traditional medicines.
What are the risk classes for medical devices under ZAMRA?
ZAMRA classifies medical devices into four risk classes based on GHTF/IMDRF guidelines: Class A (Low Risk), Class B (Low-to-Moderate Risk), Class C (Moderate-to-High Risk), and Class D (High Risk).
Do I need a local technical representative (LTR) to register a medical device in Zambia?
Yes. Foreign manufacturers cannot register products directly with ZAMRA. You must appoint a legally registered Zambian wholesale dealer or regulatory agent to act as your Local Technical Representative (LTR). The registration certificate is issued in the name of this local partner.
How long is a ZAMRA medical device registration valid?
Once issued, a ZAMRA marketing authorization certificate is valid for 5 years. The LTR must manage post-market compliance and submit renewal applications at least 6 months before the expiration date.
Can I transfer my ZAMRA registration to a new LTR?
Yes, but the transfer requires the voluntary cooperation of the incumbent LTR, who must sign off on the variation and surrender the original certificate. If the LTR refuses, the manufacturer may be forced to submit a completely new registration application, halting imports during the 9-to-12 month evaluation period.